Method for carrying out terminal group allylation modification on natural amino acid or polypeptide
By using acrylate derivatives to react with natural amino acids or polypeptides under blue light irradiation in an inert gas atmosphere, high-efficiency end-group allylation modification without metal catalysis is achieved, and the environment caused by heavy metal catalysis in the prior art is solved. Pollution and challenges to the modification of diverse amino acid skeletons, with high yield and environmental protection characteristics.
Patent Information
- Application Number
- CN202410946376.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-15
- Publication Date
- 2024-11-12
AI Technical Summary
In the prior art, heavy metal catalysts are often used when decarboxylation and allylating modification of amino acids, which lead to environmental pollution and challenges the modification of diverse amino acid skeletons, and lacks metal-free, green and efficient methods.
Under an inert gas atmosphere, an acrylate derivative with a pulling electron group at the beta position is used to react with a natural amino acid or polypeptide, base and photocatalyst under blue light irradiation, and end-allyl groups are performed by free radical nucleophilic addition reaction. The chemical modification avoids the use of metal catalysts.
It has achieved metal-free catalyzed high-efficiency amino acid or polypeptide terminal allylation, with high yield, simple operation, atomic economical and environmentally friendly, and is suitable for a variety of natural amino acids and polypeptides, providing a green synthesis pathway.
Smart Images

Figure CN118930602A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of organic chemical synthesis, and in particular relates to a method for performing terminal allylation modification on natural amino acids or polypeptides. Background Art
[0002] Amino acids are one of the many bioactive macromolecules that build biological organisms and are the basic materials for building cells and repairing tissues. Amino acids can provide energy for body and brain activities and are the source of all life. In addition, amino acids have been widely used in cosmetics, agricultural science, medicine, biotechnology and other fields due to their unique structural characteristics. In particular, the diversity of side chain modifications presents a very special three-dimensional structure, which makes this type of synthetic research on the modification of amino acid side chain residues arouse great interest in the organic synthesis community.
[0003] In the prior art, most of the decarboxylation coupling reactions of amino acids use relatively expensive heavy metal catalysts, which will bring immeasurable harm to the environment, and many of them are targeted at a few of the most active proteinogenic amino acids, which greatly limits industrial applications. Most of the allylation reactions of carboxylic acid compounds are also carried out using metal catalysis for decarboxylation and allyl reagents with good leaving groups, such as allyl halides, allyl methanesulfonate, allyl phosphate or allyl carbonate, but the preparation and reaction process of such allyl reagents will inevitably produce stoichiometric salt waste, which will also bring certain harm to the environment. In view of the strong drive for biological needs and environmentally friendly chemistry in recent years, the concept of "green chemistry" has become increasingly popular, so the development of metal-free, mild, efficient and green solutions is extremely attractive for organic synthesis research.
[0004] However, the development of decarboxylative allylation protocols for aminocarboxylates and bioactive molecules has been challenging due to the different sensitivities of various amino acid backbones. It is also very attractive to develop metal-free cross-coupling protocols that are compatible with bioactive molecules. Although conjugate addition, cross-coupling, heterocyclic reactions, and Minisi-type reactions have been achieved, the exploration of complementary free radical-related allylation techniques is still in its infancy.
[0005] Photoredox catalysis is a mild approach to amino acid modification that has emerged in recent years, generating a sizeable reaction toolbox capable of modifying nearly all typical amino acids. These reactions are characterized by their mild, physiologically compatible conditions, thus greatly increasing their applicability for amino acid modification. Here, we developed a photoredox-promoted decarboxylative allylation protocol that is well tolerated for a broad range of amino acids. The desired decarboxylative allylation products were obtained in high yields in a metal-free manner under mild and efficient conditions. Summary of the invention
[0006] In order to overcome the shortcomings and deficiencies of the prior art, the object of the present invention is to provide a method for terminal allylation modification of natural amino acids or polypeptides.
[0007] The present invention is achieved by a method for terminal allyl modification of natural amino acids or polypeptides, the method comprising the following steps:
[0008] (1) Under an inert gas atmosphere, an acrylate derivative with an electron-withdrawing group at the β position, a natural amino acid or peptide, a base, and a photocatalyst are added to a reaction solvent, and the reaction is stirred for 3 to 6 hours at room temperature under blue light irradiation.
[0009] The chemical structural formula of the natural amino acid is:
[0010]
[0011] The chemical structural formula of the acrylate derivative is:
[0012]
[0013] (2) After the reaction is complete as monitored by TLC, the reaction solution obtained in step (1) is filtered, the solvent is removed, and the mixture is purified to obtain a compound in which the amino acid or polypeptide terminal group is allylated;
[0014] The chemical structural formula of the compound in which the amino acid terminal group is allylated is:
[0015]
[0016] Among them, R 1 Any one selected from twenty natural amino acids;
[0017] R 2 Any one selected from hydrogen, methyl or methoxy, aldehyde, cyano, nitro, tert-butyl, trifluoromethyl, fluoro, chloro, bromo, trimethylsilaneethynyl, fused aryl, heteroaryl, pentafluorophenyl, 2,4-dichlorophenyl, cycloalkyl and straight-chain alkyl.
[0018] Specifically, in step (1), the acrylate derivative is selected from methyl 2-(acetoxy(phenyl)methyl)acrylate, methyl 2-(acetoxy(m-tolyl)methyl)acrylate, methyl 2-(acetoxy(4-methoxyphenyl)methyl)acrylate, methyl 2-(acetoxy(4-formylphenyl)methyl)acrylate, methyl 2-(acetoxy(4-cyanophenyl)methyl)acrylate, methyl 2-(acetoxy(4-nitrophenyl)methyl)acrylate, methyl 2-(acetoxy(4-(tert-butyl)phenyl)methyl)acrylate, methyl 2-(acetoxy(4-(trifluoromethyl)phenyl)methyl)acrylate, methyl 2-(acetoxy(4-fluorophenyl)methyl)acrylate, methyl 2-(acetoxy(4-chlorophenyl)methyl)acrylate, methyl 2-(acetoxy(4-bromophenyl)methyl)acrylate, methyl 2-(acetoxy(4-(trimethylsilyl)ethynyl)methyl)acrylate, methyl 2-(acetoxy(naphthalene-2-yl)methyl)acrylate, methyl 2-(acetoxy(furan-2-yl)methyl)acrylate, methyl 2-(acetoxy(thiophen-2-yl)methyl)acrylate, methyl 2-(acetoxy(pentafluorophenyl)methyl)acrylate, methyl 2-(acetoxy(2,4-dichlorophenyl)methyl)acrylate, methyl 2-(acetoxy(cyclohexyl)methyl)acrylate, methyl 3-acetoxy Any one of methyl oxy-2-methylenehexanoate, (1R, 2R, 5R)-2-isopropyl-5-methylcyclohexyl-2-(acetoxy(2,4-dichlorophenyl)methyl)acrylate, methyl 3-acetoxy-5,9-dimethyl-2-methylene-8-enoate, cholesteryl-2-(acetoxy(2,4-dichlorophenyl)methyl)acrylate, and galactose-2-(acetoxy(2,4-dichlorophenyl)methyl)acrylate.
[0019] In step (1), the natural amino acid is selected from N-tert-butoxycarbonyl-L-alanine, N-tert-butoxycarbonyl-L-arginine, N,N′-di-tert-butoxycarbonyl-L-asparagine, N-tert-butoxycarbonyl-L-aspartic acid, N-tert-butoxycarbonyl-L-cysteine, N,N′-di-tert-butoxycarbonyl-L-glutamine, N-tert-butoxycarbonyl-L-glutamic acid, N-tert-butoxycarbonyl-L-glycine, N,N′-di-tert-butoxycarbonyl-L-histidine, N-tert-butoxycarbonyl-L-isoleucine, N-tert-butoxycarbonyl-L-leucine, N , any one of N′-di-tert-butoxycarbonyl-L-lysine, N-tert-butoxycarbonyl-L-methionine, N-tert-butoxycarbonyl-L-phenylalanine, N-tert-butoxycarbonyl-L-proline, N-tert-butoxycarbonyl-L-serine, N-tert-butoxycarbonyl-L-threonine, N,N′-di-tert-butoxycarbonyl-L-tryptophan, N-tert-butoxycarbonyl-L-tyrosine, and N-tert-butoxycarbonyl-L-valine; the polypeptide is selected from any one of glycine tripeptide, L-angesine, acetyl tetrapeptide-5, acetyl tetrapeptide-11, and L-glycine-glycine-white tripeptide.
[0020] Preferably, the heteroaryl group is, for example, furyl or thienyl; the cycloalkyl group is cyclohexyl; and the linear alkyl group is n-butyl.
[0021] Preferably, in step (1), the base is selected from any one of dipotassium hydrogen phosphate, trisodium phosphate, sodium acetate, tripotassium phosphate, sodium bicarbonate, triethylenediamine, 4-dimethylaminopyridine, triphenylphosphine, and triethylamine.
[0022] Preferably, in step (1), the reaction solvent is selected from any one of dichloromethane, 1,2-dichloroethane, acetonitrile, methanol, isopropanol, tetrahydrofuran, toluene, dimethyl sulfoxide, N,N-dimethylformamide and ethylene glycol dimethyl ether.
[0023] Preferably, in step (1), the catalyst is selected from any one of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate, 2,4,5,6-tetrakis(9-carbazolyl)-isophthalonitrile, eosin Y, tris(2,2′-bipyridine)ruthenium di(hexafluorophosphate) and tris(1,10-phenanthroline)ruthenium(II) bis(hexafluorophosphate), riboflavin and rhodamine B.
[0024] Preferably, in step (1), the molar volume ratio of the acrylate derivative, amino acid, base, catalyst and reaction solvent is 0.24-1.2 mmol: 0.2-1.0 mmol: 0.5-2.5 mmol: 0.01-0.05 mmol: 2-10 mL.
[0025] Preferably, in step (1), the catalyst is 3,6,di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate, the base is tripotassium phosphate, and the reaction solvent is dichloromethane.
[0026] Preferably, in step (1), the reaction is stirred for 6 h under inert gas atmosphere, blue light irradiation and room temperature.
[0027] Preferably, in step (2), the filtration is through an F-caliber sand core funnel, the solvent removal is through a vacuum rotary evaporator to remove the reaction solvent, the purification is through thin layer chromatography / column chromatography, and the developing solvent system is petroleum ether / ethyl acetate = 9 / 1.
[0028] The present invention overcomes the deficiencies of the prior art and provides a method for terminal allylation modification of natural amino acids or polypeptides, comprising the steps of:
[0029] (1) Under an inert gas atmosphere, an acrylate derivative, a natural amino acid or a polypeptide, a base, and a photocatalyst are added to a reaction solvent, and the reaction is stirred for 6 hours under blue light irradiation and room temperature to obtain a reaction solution, wherein the chemical equation of the reaction is:
[0030]
[0031] In this reaction formula, R 1 Any one selected from twenty natural amino acids;
[0032] R 2 Any one selected from hydrogen, methyl or methoxy, aldehyde, cyano, nitro, tert-butyl, trifluoromethyl, fluoro, chloro, bromo, trimethylsilaneethynyl, fused aryl, heteroaryl, pentafluorophenyl, 2,4-dichloro, cycloalkyl and straight-chain alkyl.
[0033] (2) removing the reaction solvent from the reaction solution obtained in step (1), and then purifying by thin layer chromatography / column chromatography to obtain a product of amino acid terminal allylation modification, i.e., compound 3 in the above reaction formula.
[0034] The present invention directly uses acrylate derivatives to replace pre-modulated activated allyl reagents as electrophilic reagents, selects amino acids or polypeptides for decarboxylation to introduce free radical fragments, and then irradiates with blue light at room temperature to react, and obtains the final product through free radical nucleophilic addition reaction.
[0035] Compared with the shortcomings and deficiencies of the prior art, the present invention has the following beneficial effects:
[0036] (1) The acrylate derivatives used in the method of the present invention are acrylate compounds with an electron-withdrawing group at the β position, which are simple to synthesize and have a high conversion rate. The applicable substrate range is wide, such as various substituted phenyl groups and alkyl groups on the acrylate derivatives, and the preparation cost is low. In addition, the method of the present invention has simple steps, convenient operation, high product yield, and does not use any metal compounds, and has the characteristics of high atom economy and green environmental protection.
[0037] (2) The present invention provides a method for terminal allylation modification of natural amino acids or polypeptides, which can be used as organic synthetic building blocks for various derivatizations by utilizing the nucleophilic addition reaction of the terminal olefinic group and the free radical obtained after terminal decarboxylation, thereby providing a green approach for the subsequent biological modification of polypeptides and proteins, and also has potential application value in other natural products, biological and drug molecules with similar structures. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 is the hydrogen nuclear magnetic resonance spectrum of compound 3 in Example 1 of the present invention;
[0039] Figure 2 is the carbon NMR spectrum of compound 3 in Example 1 of the present invention;
[0040] Figure 3 is the hydrogen nuclear magnetic resonance spectrum of compound 5 in Example 2 of the present invention;
[0041] Figure 4 is the carbon NMR spectrum of compound 5 in Example 2 of the present invention;
[0042] Figure 5 is the hydrogen nuclear magnetic resonance spectrum of compound 7 in Example 3 of the present invention;
[0043] Figure 6 is the carbon NMR spectrum of compound 7 in Example 3 of the present invention;
[0044] Figure 7 is the hydrogen nuclear magnetic resonance spectrum of compound 9 in Example 4 of the present invention;
[0045] Figure 8 is the carbon NMR spectrum of compound 9 in Example 4 of the present invention;
[0046] Fig. 9 is the hydrogen nuclear magnetic resonance spectrum of compound 11 in Example 5 of the present invention;
[0047] Fig.10 is the carbon NMR spectrum of compound 11 in Example 5 of the present invention;
[0048] Fig.11 is the hydrogen nuclear magnetic resonance spectrum of compound 19 in Example 6 of the present invention;
[0049] Fig.12 is the carbon NMR spectrum of compound 19 in Example 6 of the present invention;
[0050] Fig.13 is the hydrogen nuclear magnetic resonance spectrum of compound 24 in Example 7 of the present invention;
[0051] Fig.14 is the carbon NMR spectrum of compound 24 in Example 7 of the present invention;
[0052] Fig.15 is the hydrogen nuclear magnetic resonance spectrum of compound 24 in Example 8 of the present invention;
[0053] Fig.16 It is the carbon NMR spectrum of compound 24 in Example 8 of the present invention. DETAILED DESCRIPTION
[0054] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0055] Example 1
[0056] (1) In a 10 mL Shrek tube, under an inert gas environment, 0.2 mmol of N-tert-butyloxycarbonyl-L-phenylalanine, 0.24 mmol of methyl 2-(acetoxy(phenyl)methyl)acrylate, 0.01 mmol of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate and 0.5 mmol of tripotassium phosphate were added, and 2 mL of dichloromethane was added. The mixture was stirred for 6 h under argon gas, room temperature and 54 W blue light irradiation. The reaction equation is:
[0057]
[0058] (2) After the reaction was completed as monitored by TLC, the reaction solution was filtered using an F-caliber sand core funnel, and the solvent was removed using a vacuum rotary evaporator. The product was separated by thin layer chromatography using a petroleum ether / ethyl acetate system (9 / 1) as the developing solvent. The product was a white solid compound 3 with a yield of 92%.
[0059] Compound 3 was characterized and the data are as follows:
[0060] Mp: 83-85℃. 1H NMR (400MHz, Chloroform-d) δ7.70 (s, 1H), 7.31-7.27 (m, 2H), 7.25-7.18 (m, 6H), 7.13-7.11 (m, 2H), 4.82 (d, J=8 .5Hz, 1H), 4.03-4.00(m, 1H), 3.82(s, 3H), 3.03-2.98(m, 1H), 2.74-2.70(m, 1H), 2.66-2.59(m, 2H), 1.39(s, 9H). 13 C NMR (101MHz, Chloroform-d) δ169.7, 155.5, 141.3, 138.2, 135.2, 129.9, 129.7, 129.5, 128.6, 128.5, 126.5, 79.0, 52.7, 52.4 , 42.6, 31.2, 28.5.IR (KBr): 3550, 3478, 3414, 3237, 2977, 1714, 1637, 1496, 1365, 1275, 1260, 1169, 764, 749, 700, 616, 472cm- 1 .HRMS(ESI)m / z:[M+H] + Calcd.for: C 24 H 30 NO4396.2175; Found 396.2168.
[0061] NMR spectra Figures 1-2 As shown, the above characterization results indicate that compound 3 is (E)-2-benzylidene-4-((tert-butyloxycarbonyl)amino)-5-phenylpentanoic acid methyl ester.
[0062] Example 2
[0063] (1) In a 10 mL Shrek tube, under an inert gas environment, 0.2 mmol of N-tert-butyloxycarbonyl-L-methionine, 0.24 mmol of methyl 2-(acetoxy(phenyl)methyl)acrylate, 0.01 mmol of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate and 0.5 mmol of tripotassium phosphate were added, and 2 mL of dichloromethane was added. The mixture was stirred for 6 h under argon gas, room temperature and 54 W blue light irradiation. The reaction equation is:
[0064]
[0065] (2) After the reaction was completed as monitored by TLC, the reaction solution was filtered using an F-caliber sand core funnel, and the solvent was removed using a vacuum rotary evaporator. The product was separated by thin layer chromatography using a petroleum ether / ethyl acetate system (9 / 1) as the developing solvent. The product was a yellow solid compound 5 with a yield of 86%.
[0066] Compound 5 was characterized and the data are as follows:
[0067] Mp: 98-101℃. 1 H NMR (400MHz, Chloroform-d) δ7.78 (s, 1H), 7.41-7.30 (, 5H), 4.45 (d, J=9.4Hz, 1H), 3.97-3.88 (m, 1H) , 3.82 (s, 3H), 2.67 (d, J=7.4Hz, 2H), 2.52-2.40 (m, 2H), 2.05 (s, 3H), 1.79-1.58 (m, 2H), 1.38 (s, 9H). 13 C NMR (101MHz, Chloroform-d) δ169.1, 155.6, 141.6, 135.6, 130.1, 129.2, 128.7, 128.6, 79.1, 52.3, 50.5 , 35.7, 32.8, 30.6, 28.4, 15.6.IR (KBr): 3366, 3004, 2985, 1712, 1364, 1275, 1260, 1167, 763, 749, 704cm -1 .HRMS(ESI)m / z:[M+H] + Calcd.for::C 20 H 30 NO4S 380.1896; Found 380.1892.
[0068] NMR spectra Figures 3-4 As shown, the above characterization results indicate that compound 5 is methyl (E)-2-benzylidene-4-((tert-butoxycarbonyl)amino)-6-(methylthio)hexanoate.
[0069] Example 3
[0070] (1) In a 10 mL Shrek tube, under an inert gas environment, 0.2 mmol of N, N′-di-tert-butyloxycarbonyl-L-tryptophan, 0.24 mmol of methyl 2-(acetoxy(phenyl)methyl)acrylate, 0.01 mmol of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate and 0.5 mmol of tripotassium phosphate were added, and 2 mL of dichloromethane was added. The mixture was stirred for 6 h under argon gas, room temperature and 54 W blue light irradiation. The reaction equation is:
[0071]
[0072] (2) After the reaction was completed as monitored by TLC, the reaction solution was filtered using an F-caliber sand core funnel, the solvent was removed by a vacuum rotary evaporator, and the product was separated by thin layer chromatography using a petroleum ether / ethyl acetate system (9 / 1) as the developing solvent. The product was a colorless oily compound 7 with a yield of 93%.
[0073] Compound 7 was characterized and the data are as follows:
[0074] 1 H NMR (400MHz, Chloroform-d) δ8.18 (d, J=8.1Hz, 1H), 7.74-7.70 (m, 2H), 7.40 (s, 1H), 7.37-7.33 (m, 1H), 7.29-7.25 (m, 1H), 7.18-7.14 (m, 1H), 7.08-6 .97(m, 4H), 5.03(d, J=8.1Hz, 1H), 4.23-4.12(m, 1H), 3.80(s, 3H), 3.19-3. 15(m, 1H), 2.82-2.77(m, 1H), 2.75-2.64(m, 2H), 1.67(s, 9H), 1.44(s, 9H). 13 CNMR (101MHz, Chloroform-d) δ169.7, 155.6, 149.8, 141.5, 135.7, 135.0, 130.9, 129.9, 129.3, 128.6, 128.4, 124.5, 124.0, 122.8, 119.7, 117.2 ,115.3,79.0,83.5,52.3,51.4,32.1,31.4,28.5,28.3.IR(KBr):3379,2 976, 1712, 1505, 1453, 1367, 1256, 1166, 1084, 1017, 856, 765, 749, 693cm -1 .HRMS(ESI)m / z:[M+H] + Calcd.for: C 19 H 28 NO5350.1967;Found 350.1959.
[0075] NMR spectra Figures 5-6 As shown, the above characterization results indicate that compound 7 is (E)-2-(2-((tert-butyloxycarbonyl)amino)-4-(methoxycarbonyl)-5-phenylpent-4-en-1-yl)-1H-indole-1-carboxylic acid tert-butyl ester.
[0076] Example 4
[0077] (1) In a 10 mL Shrek tube, under an inert gas environment, 0.2 mmol of N-tert-butyloxycarbonyl-L-phenylalanine, 0.24 mmol of methyl 2-(acetoxy(4-methoxyphenyl)methyl)acrylate, 0.01 mmol of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate and 0.5 mmol of tripotassium phosphate were added, and 2 mL of dichloromethane was added. The mixture was stirred and reacted for 6 h under argon gas, room temperature and 54 W blue light irradiation. The reaction equation is:
[0078]
[0079] (2) After the reaction was completed as monitored by TLC, the reaction solution was filtered using an F-caliber sand core funnel, and the solvent was removed using a vacuum rotary evaporator. The product was separated by thin layer chromatography using a petroleum ether / ethyl acetate system (5 / 1) as the developing solvent. The product was a white solid compound 9 with a yield of 82%.
[0080] Compound 9 was characterized and the data are as follows:
[0081] Mp: 90-93℃. 1 H NMR (400MHz, Chloroform-d) δ7.63 (s, 1H), 7.34-7.23 (m, 5H), 7.05-7.03 (m, 2H), 6.68-6.66 (m, 2H), 5.05 (d, J=8.0Hz, 1 H), 4.04-3.95 (m, 1H), 3.81 (s, 3H), 3.79 (s, 3H), 3.12-3.07 (m, 1H), 2.77-2.73 (m, 1H), 2.69-2.60 (m, 2H), 1.39 (s, 9H). 13 CNMR (101MHz, Chloroform-d) δ170.2, 160.0, 155.6, 141.0, 138.4, 131.5, 129.8, 128.6, 127.5, 126.5, 114 .0, 79.0, 55.3, 53.0, 52.3, 42.8, 30.9, 28.5.IR (KBr): 3414, 3005, 1706, 1510, 1275, 1175, 764, 749, 616cm- 1 .HRMS(ESI)m / z:[M+H] + Calcd.for: C25H32NO5426.2280; Found 426.2271.
[0082] NMR spectra Figures 7-8As shown, the above characterization results indicate that compound 9 is (E)-4-((tert-butyloxycarbonyl)amino)-2-(4-methoxybenzylidene)-5-phenylpentanoic acid methyl ester.
[0083] Example 5
[0084] (1) In a 10 mL Shrek tube, under an inert gas environment, 0.2 mmol of N-tert-butyloxycarbonyl-L-phenylalanine, 0.24 mmol of methyl 2-(acetoxy(4-cyanophenyl)methyl)acrylate, 0.01 mmol of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate and 0.5 mmol of tripotassium phosphate were added, and 2 mL of dichloromethane was added. The mixture was stirred and reacted for 6 h under argon gas, room temperature and 54 W blue light irradiation. The reaction equation is:
[0085]
[0086] (2) After the reaction was completed as monitored by TLC, the reaction solution was filtered using an F-caliber sand core funnel, the solvent was removed by a vacuum rotary evaporator, and the product was separated by thin layer chromatography using a petroleum ether / ethyl acetate system (5 / 1) as the developing solvent. The product was a white solid compound 11 with a yield of 80%.
[0087] Compound 11 was characterized and the data are as follows:
[0088] Mp: 102-107℃. 1 H NMR (400MHz, Chloroform-d) δ7.64 (s, 1H), 7.45-7.43 (m, 2H), 7.32-7.24 (m, 3H), 7.18-7.16 (m, 4H), 4. 78(d, J=8.6Hz, 1H), 3.96-3.88(m, 1H), 3.84(s, 3H), 3.03-2.98(m, 1H), 2.67-2.56(m, 3H), 1.39(s, 9H). 13 C NMR (101MHz, Chloroform-d) δ168.9, 155.4, 139.8, 138.9, 138.0, 133.0, 132.3, 129.7, 129.5, 128.6, 126.8, 118.6, 111.9, 79.3, 52.9, 52.6, 42.7, 31.1, 28.5.IR (KBr): 2228, 1713, 1500, 1275, 1169, 764, 749, 701, 533cm -1 .HRMS(ESI)m / z:[M+H] + Calcd.for::C 25 H 29N2O4421.2127;Found 421.2118.
[0089] NMR spectra Figures 9-10 As shown, the above characterization results indicate that compound 11 is (E)-4-(tert-butyloxycarbonyl)amino)-2-(4-cyanobenzylidene)-5-phenylpentanoic acid methyl ester.
[0090] Example 6
[0091] The acrylate derivatives used in this embodiment are acrylate derivatives with the molecular structure of natural product menthol. The synthesis steps of the acrylate derivatives are as follows:
[0092] (1) Under nitrogen protection and room temperature, add 24 mmol of menthol to a dichloromethane solution, add 40 mmol of triethylamine at 0°C, and stir for 0.5 h. Then, drop 20 mmol of acrylyl chloride in dichloromethane solution at 0°C into the above reaction solution, stir and react at room temperature for 12 h to obtain a reaction mixture. The reaction equation is:
[0093]
[0094] (2) The reaction mixture was quenched by adding saturated ammonium chloride solution, extracted with ether three times, the organic phases were combined, dried over anhydrous sodium sulfate, the solvent was removed under reduced pressure, and the product was separated by column silica gel chromatography using a petroleum ether / ethyl acetate system (9 / 1) as the developing solvent. The product was a colorless liquid 14 with a yield of 93%.
[0095] (3) Under nitrogen protection and room temperature, 20 mmol of 2,4-dichlorobenzaldehyde, 24 mmol of the above compound 14, and 10 mmol of triethylenediamine were dissolved in tetrahydrofuran, and stirred at room temperature for one week to obtain a reaction mixture. The reaction equation is:
[0096]
[0097] (4) The reaction mixture was subjected to silica gel column chromatography to separate the product. The developing solvent was petroleum ether / ethyl acetate system (9 / 1). The product was a colorless liquid 16. The yield was 89%.
[0098] (5) At room temperature, compound 16 and 4-dimethylaminopyridine are dissolved in dichloromethane, and acetic anhydride solution is slowly added dropwise, and stirred at room temperature for 2 to 3 hours to obtain a reaction mixture, wherein the molar ratio of 16, acetic anhydride and 4-dimethylaminopyridine is 1:3:0.2. The reaction equation is:
[0099]
[0100] (6) The reaction mixture was separated by column silica gel chromatography, the developing solvent was dichloromethane, and the product was a colorless liquid 18 with a yield of 85%. On this basis, the colorless liquid 18 was used as an acrylic acid ester derivative to react with N-tert-butyloxycarbonyl-L-phenylalanine, and the specific process was as follows:
[0101] (7) In a 10 mL Shrek tube, under an inert gas environment, 0.2 mmol of N-tert-butyloxycarbonyl-L-phenylalanine, 0.24 mmol of the above colorless liquid compound 18, 0.01 mmol of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate and 0.5 mmol of tripotassium phosphate were added, and 2 mL of dichloromethane was added. The mixture was stirred and reacted for 6 h under argon gas, room temperature and 54 W blue light irradiation. The reaction equation is:
[0102]
[0103] (2) After the reaction was completed as monitored by TLC, the reaction solution was filtered using an F-caliber sand core funnel, and the solvent was removed using a vacuum rotary evaporator. The product was separated by thin layer chromatography using a petroleum ether / ethyl acetate system (9 / 1) as the developing solvent. The product was a colorless oily compound 19 with a yield of 85%.
[0104] Compound 19 was characterized and the data are as follows:
[0105] 1 H NMR (400MHz, Chloroform-d) δ7.68 (d, J=13.7Hz, 1H), 7.35-7.34 (m, 1H), 7.28-7.21 (m, 3H ), 7.16-7.10 (m, 2H), 6.92 (d, J=11.0Hz, 2H), 4.88-4.75 (m, 1H), 3.90-3.73 (m, 1H), 3.01- 2.97(m, 1H), 2.55-2.44(m, 3H), 2.14-2.05(m, 1H), 1.94-1.85(m, 1H), 1.74-1.67(m, 2H), 1.59-1.43(m, 3H), 1.40(s, 9H), 1.15-0.99(m, 2H), 0.95-0.89(m, 6H), 0.81-0.77(m, 3H). 13C NMR (101MHz, Chloroform-d) δ168.1, 167.8, 155.4, 138.2, 137.3, 136.6, 134.7, 134.5, 134.4, 133.2, 133.1, 132.4, 130.6, 130.5, 129.5, 128.5, 128.5, 127.1, 126.5, 126.4, 79.1, 75.5, 53.4, 47.2, 47.1, 42.8, 42.5, 40.9, 40.7, 34.3 , 34.3, 31.6, 31.5, 30.6, 30.3, 28.5, 26.7, 23.7, 23.7, 22.2, 22.2, 20.8, 16.7, 16.7.1R (KBr): 3563, 3417, 2956, 292 8, 2869, 1712, 1637, 1618, 1583, 1497, 1468, 1365, 1275, 1260, 1227, 1173, 1098, 1043, 961, 819, 764, 749, 700, 465cm -1 .HRMS(ESI)m / z:[M+H] + Calcd.for: C 33 H 44 NO4Cl2588.2647; Found 588.2654.
[0106] NMR spectra Figures 11-12 As shown, the above characterization results show that compound 19 is (1R, 2R, 5R)-2-isopropyl-5-methylcyclohexyl-4-((tert-butyloxycarbonyl)amino)-2-((E)-2,4-dichlorobenzylidene)-5-phenylpentanoate.
[0107] Example 7
[0108] The acrylate derivative used in this embodiment is an acrylate derivative with a molecular structure of natural product cholesterol. The synthesis steps of the acrylate derivative are as follows:
[0109] (1) Under nitrogen protection and room temperature, 24 mmol of cholesterol was added to a dichloromethane solution, and 40 mmol of triethylamine was added at 0°C, and the mixture was stirred for 0.5 h. Then, a 20 mmol dichloromethane solution of acryloyl chloride was added dropwise to the reaction solution at 0°C, and the mixture was stirred for 12 h at room temperature to obtain a reaction mixture. The reaction equation is:
[0110]
[0111] (2) The reaction mixture was quenched by adding saturated ammonium chloride solution, extracted with ether three times, the organic phases were combined, dried over anhydrous sodium sulfate, the solvent was removed under reduced pressure, and the product was separated by column silica gel chromatography using a petroleum ether / ethyl acetate system (9 / 1) as the developing solvent. The product was a white solid 21 with a yield of 72%.
[0112] (3) Under nitrogen protection and room temperature, 20 mmol of 2,4-dichlorobenzaldehyde, 24 mmol of the above compound 21, and 10 mmol of triethylenediamine were dissolved in tetrahydrofuran and stirred at room temperature for 1 week to obtain a reaction mixture. The reaction equation is:
[0113]
[0114] (4) The reaction mixture was subjected to silica gel column chromatography to separate the product. The developing solvent was petroleum ether / ethyl acetate system (9 / 1). The product was a white solid 22 with a yield of 68%.
[0115] (5) Under room temperature, compound 22 and 4-dimethylaminopyridine are dissolved in dichloromethane, and acetic anhydride solution is slowly added dropwise, and the mixture is allowed to react at room temperature for 2 to 3 hours to obtain a reaction mixture, wherein the molar ratio of 22, acetic anhydride and 4-dimethylaminopyridine is 1:3:0.2. The reaction equation is:
[0116]
[0117] (6) The reaction mixture was separated into products by column silica gel chromatography with dichloromethane as the developing solvent. The product was white solid 23 with a yield of 88%.
[0118] On this basis, the above-mentioned white solid compound 23 was used as an acrylic acid ester derivative to react with N-tert-butyloxycarbonyl-L-phenylalanine. The specific process is as follows:
[0119] (7) In a 10 mL Shrek tube, under an inert gas environment, 0.2 mmol of N-tert-butyloxycarbonyl-L-phenylalanine, 0.24 mmol of the above-mentioned white native compound 23, 0.01 mmol of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate and 0.5 mmol of tripotassium phosphate were added, and 2 mL of dichloromethane was added. The mixture was stirred for 12 h under argon gas, room temperature and 54 W blue light irradiation. The reaction equation is:
[0120]
[0121] (2) After the reaction was completed as monitored by TLC, the reaction solution was filtered using an F-caliber sand core funnel, and the solvent was removed by a vacuum rotary evaporator. The product was separated by thin layer chromatography using a petroleum ether / ethyl acetate system (9 / 1) as the developing solvent. The product was a white solid compound 24 with a yield of 90%.
[0122] Compound 24 was characterized and the data are as follows:
[0123] Mp: 58-60℃. 1 H NMR (400MHz, Chloroform-d) δ7.65 (s, 1H), 7.34 (d, J=1.5Hz, 1H), 7.26-7.21 (m, 3H), 7.13-7.11 (m, 2 H), 6.97-6.91(m, 2H), 5.42-5.39(m, 1H), 4.84-4.81(m, 1H), 4.79-4.71(m, 1H), 3.87-3.79(m, 1H), 2. 99-2.94(,1H),2.54-2.38(m,5H),2.04-1.87(m,5H),1.61-1.43(m,8H),1.40(s,9H),1.30-1.08(m, 9H), 1.05 (s, 3H), 1.02-0.95 (m, 3H), 0.92 (d, J=6.5Hz, 3H), 0.87 (dd, J=6.7, 2.0Hz, 6H), 0.68 (s, 3H). 13 C NMR (101MHz, Chloroform-d) δ167.6, 155.3, 139.6, 138.1, 137.1, 134.6, 134.4, 1 33.4, 132.5, 130.6, 129.5, 129.5, 128.5, 127.1, 126.5, 123.0, 79.1, 75.2, 56.7, 56.2, 53.3, 50.1, 42.6, 42.4, 39.8, 39.6, 38.2, 37.1, 36.7, 36.3, 35.9, 32.0, 31. 9, 30.8, 28.5, 28.4, 28.1, 27.9, 24A, 23.9, 23.0, 22.7, 21.1, 19.5, 18.8, 12.0.IR (K(KBr): 3419, 2935, 2867, 1714, 1497, 1467, 1387, 1365, 1275, 1261, 1227, 1171, 1099, 865, 764, 749, 700, 463cm- 1 .HRMS(ESI)m / z:[M+H) + Calcd.for: C 50 H 70NO4Cl2818.4682; Found 818.4677.
[0124] NMR spectra Figures 13-14 As shown, the above characterization results indicate that compound 24 is (3S, 8S, 9S, 10R, 13R, 14S, 17R)-10,13-dimethyl-17-((R)-6-methylheptyl-2-yl)-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopentadienyl[a]phenanthrene-3-yl-4-((tert-butoxycarbonyl)amino)-2-((E)-2,4-dichlorobenzylidene) 5-phenylpentanoate.
[0125] Example 8
[0126] In order to further illustrate the universal applicability of this scheme, in this example, a functional polypeptide glycyl-glycyl-L-leucine was subjected to terminal allylation modification, and the specific process was as follows:
[0127] (1) 4.08 mmol of glycyl-glycyl-L-leucine was dissolved in a two-phase mixed solution of water and 1,4-dioxane (1:1, 16 mL), and then 11.42 mmol of triethylamine was added, and then 4.89 mmol of di-tert-butyl dicarbonate was slowly dripped into the above reaction solution at 0°C, and stirred at room temperature for 18 hours to obtain a reaction mixture. Then 40 mL of 10% citric acid solution was slowly dripped into the reaction mixture, stirred at room temperature for 1 hour, and the pH of the solution was adjusted to 4-5. Then, it was extracted 3 times with 20 mL of ethyl acetate, and the combined organic layer was washed with brine and dried over anhydrous sodium sulfate. After removing the solvent under reduced pressure, the corresponding white solid product 26 was obtained with a yield of 72%. The reaction equation is:
[0128]
[0129] On this basis, the white solid 26 was reacted with an acrylate derivative, and the specific process was as follows:
[0130] (2) In a 10 mL Shrek tube, under an inert gas environment, 0.2 mmol of N-(tert-butyloxycarbonyl)-glycyl-glycyl-L-leucine, 0.24 mmol of 2-(acetoxy(4-methoxyphenyl)methyl)acrylate, 0.01 mmol of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate and 0.5 mmol of tripotassium phosphate were added, and 2 mL of dichloromethane was added. The mixture was stirred for 6 h under argon gas, room temperature and 54 W blue light irradiation. The reaction equation is:
[0131]
[0132] (2) After the reaction was completed as monitored by TLC, the reaction solution was filtered using an F-caliber sand core funnel, the solvent was removed by a vacuum rotary evaporator, and the product was separated by thin layer chromatography using a dichloromethane / methanol system (20 / 1) as the developing solvent. The product was a white solid compound 27 with a yield of 78%.
[0133] Compound 27 was characterized and the data are as follows:
[0134] Mp: 115-118℃. 1 H NMR (400MHz, DMSO-d6) δ7.87 (t, J=5.6Hz, 1H), 7.58 (s, 1H), 7.53-7.32 (m, 6H), 7.04 (t, J=6.0Hz, 1H), 4.22-4.10 (m, 1H), 3.73 (s, 3H), 3. 68-3.63 (m, 1H), 3.54-3.45 (m, 3H), 2.64-2.55 (m, 2H), 1.57-1.47 (m, 1H), 1.37 (s, 9H), 1.25-1.09 (m, 2H), 0.78 (dd, J=25.6, 6.6Hz, 6H). 13 C NMR (101MHz, DMSO-d6) δ170.0, 168.6, 168.4, 156.4, 140.2, 135.5, 130.8, 129.8, 129.2, 129.1, 78.7, 52.4, 46.6, 43.9, 42.2, 33. 9, 28.7, 24.7, 23.6, 22.1.IR (KBr): 3313, 2955, 2869, 1708, 1528, 1436, 1390, 1366, 1251, 1202, 1170, 1049, 1029, 944, 771, 702cm -1 .HRMS(ESI)m / z:[M+H] + Calcd.for: C 25 H 38 N3O6476.2761;Found476.2755.
[0135] NMR spectra Figures 15-16 As shown, the above characterization results indicate that compound 27 is methyl (S, E)-14-benzylidene-12-isobutyl-2,2-dimethyl-4,7-10-trioxo-3-oxo-5,8,11-triazapentadecan-15-oate.
[0136] Embodiments 9 to 14
[0137] The Examples 9 to 14 are substantially the same as the above examples, and the obtained products are the same, except that they are shown in Table 1 below:
[0138] Table 1 Comparison of implementation differences
[0139]
[0140] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A method for terminal allyl modification of natural amino acids or polypeptides, It is characterized in that The method comprises the following steps: (1) Under an inert gas atmosphere, an acrylate derivative with an electron-withdrawing group at the β position, a natural amino acid or peptide, a base, and a photocatalyst are added to a reaction solvent, and the reaction is stirred for 3 to 6 hours under blue light irradiation and room temperature; wherein: The chemical structural formula of the natural amino acid is: The chemical structural formula of the acrylate derivative is: (2) After the reaction is complete as monitored by TLC, the reaction solution obtained in step (1) is filtered, the solvent is removed, and the mixture is purified to obtain a compound in which the amino acid or polypeptide terminal group is allylated; The chemical structural formula of the compound in which the amino acid terminal group is allylated is: Among them, R 1 Any one selected from twenty natural amino acids; R 2 Any one selected from hydrogen, methyl or methoxy, aldehyde, cyano, nitro, tert-butyl, trifluoromethyl, fluoro, chloro, bromo, trimethylsilaneethynyl, fused aryl, heteroaryl, pentafluoro, 2,4-dichloro, cycloalkyl and straight-chain alkyl.
2. The method according to claim 1, It is characterized in that The heteroaryl group is, for example, furyl or thienyl; the cycloalkyl group is cyclohexyl; and the linear alkyl group is n-butyl.
3. The method according to claim 1, It is characterized in that In step (1), the base is selected from dipotassium hydrogen phosphate, trisodium phosphate, Any one of sodium acetate, tripotassium phosphate, sodium bicarbonate, triethylenediamine, 4-dimethylaminopyridine, triphenylphosphine, and triethylamine.
4. The method according to claim 1, It is characterized in that In step (1), the reaction solvent is selected from any one of dichloromethane, 1,2-dichloroethane, acetonitrile, methanol, isopropanol, tetrahydrofuran, toluene, dimethyl sulfoxide, N,N-dimethylformamide and ethylene glycol dimethyl ether.
5. The method according to claim 1, It is characterized in that In step (1), the catalyst is selected from any one of 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate, 2,4,5,6-tetrakis(9-carbazolyl)-isophthalonitrile, eosin Y, tris(2,2′-bipyridine)ruthenium di(hexafluorophosphate) and tris(1,10-phenanthroline)ruthenium(II) bis(hexafluorophosphate), riboflavin, and rhodamine B.
6. The method according to claim 1, It is characterized in that In step (1), the molar volume ratio of the acrylate derivative, amino acid or polypeptide, base, catalyst, and reaction solvent is 0.24-1.2 mmol: 0.2-1.0 mmol: 0.5-2.5 mmol: 0.01-0.05 mmol: 2-10 mL.
7. The method according to claim 1, It is characterized in that In step (1), the catalyst is 3,6-di-tert-butyl-9-mesityl-10-phenylacridine-10-tetrafluoroborate, the base is tripotassium phosphate, and the reaction solvent is dichloromethane.
8. The method according to claim 1, It is characterized in that In step (1), the reaction was stirred for 6 h under inert gas atmosphere, blue light irradiation and room temperature.
9. The method according to claim 1, It is characterized in that In step (2), the filtration is performed through an F-caliber sand core funnel, the solvent removal is performed by a vacuum rotary evaporator to remove the reaction solvent, and the purification is performed by thin layer chromatography / column chromatography, and the developing solvent system is petroleum ether / ethyl acetate = 9 / 1.
